Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | LAP3 | P28838 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600361 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL14066236 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL6575848 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL6012976 | 0.94 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL8426058 | 0.94 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| Benzyl Alcohol SCHEMBL27898646 | 0.92 | ALDH1A1 (0.53) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL8424336 | 0.91 | ALDH1A1 (0.56) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL8424338 | 0.91 | ALDH1A1 (0.56) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL15449774 | 0.91 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL19853604 | 0.91 | ALDH1A1 (0.52) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447297-B2 | Phase change ink containing amorphous amides | XEROX CORPORATION (US) | 2016-09-20 | — | — | US | claimed |
| US-9193883-B2 | Phase change ink containing polyester for improved image robustness | XEROX CORPORATION (US) | 2015-11-24 | — | — | US | claimed |
| US-9127180-B2 | Phase change inks comprising organic pigments | XEROX CORPORATION (US) | 2015-09-08 | — | — | US | claimed |
| US-9090791-B2 | Mixtures of ester of tartaric acid and ester of citric acid as amorphous materials for phase change inks | XEROX CORPORATION (US) | 2015-07-28 | — | — | US | claimed |
| US-9051486-B2 | Phase change ink components and methods of making the same | XEROX CORPORATION (US) | 2015-06-09 | — | — | US | claimed |
| US-20150103122-A1 | Phase Change Ink Containing Amorphous Amides | XEROX CORPORATION (US) | 2015-04-16 | — | — | US | claimed |
| US-20140368588-A1 | Phase Change Ink Containing Polyester For Improved Image Robustness | Genesee Valley Innovations, LLC | 2014-12-18 | — | — | US | claimed |
| US-8911544-B2 | Phase change ink composition | XEROX CORPORATION (US) | 2014-12-16 | — | — | US | claimed |
| US-20140352576-A1 | MIXTURES OF ESTER OF TARTARIC ACID AND ESTER OF CITRIC ACID AS AMORPHOUS MATERIALS FOR PHASE CHANGE INKS | Genesee Valley Innovations, LLC | 2014-12-04 | — | — | US | claimed |
| US-20140357772-A1 | PHASE CHANGE INK COMPOSITIONS COMPRISING MIXTURES OF ESTER OF TARTARIC ACID AND ESTER OF CITRIC ACID AS AMORPHOUS MATERIALS | Genesee Valley Innovations, LLC | 2014-12-04 | — | — | US | claimed |
| US-20140041546-A1 | PHASE CHANGE INK COMPONENTS AND METHODS OF MAKING THE SAME | XEROX CORPORATION (US) | 2014-02-13 | — | — | US | claimed |
| US-8647423-B2 | Phase change inks comprising fatty acids | XEROX CORPORATION (US) | 2014-02-11 | — | — | US | claimed |
| US-20130284057-A1 | PHASE CHANGE INKS COMPRISING ORGANIC PIGMENTS | XEROX CORPORATION (US) | 2013-10-31 | — | — | US | claimed |
| US-20130284051-A1 | PHASE CHANGE INKS COMPRISING FATTY ACIDS | XEROX CORPORATION (US) | 2013-10-31 | — | — | US | claimed |
| US-8465579-B2 | Solid ink compositions comprising crystalline esters of tartaric acid | XEROX CORPORATION (US) | 2013-06-18 | — | — | US | claimed |
| US-20120291663-A1 | PHASE CHANGE INK COMPONENTS AND METHODS OF MAKING THE SAME | XEROX CORPORATION (US) | 2012-11-22 | — | — | US | claimed |
| US-8308859-B1 | Phase change ink components and methods of making the same | XEROX CORPORATION (US) | 2012-11-13 | — | — | US | claimed |
| US-20120272860-A1 | PHASE CHANGE INK COMPONENTS AND METHODS OF MAKING THE SAME | XEROX CORPORATION (US) | 2012-11-01 | — | — | US | claimed |
| US-20120272863-A1 | SOLID INK COMPOSITIONS COMPRISING CRYSTALLINE ESTERS OF TARTARIC ACID | XEROX CORPORATION (US) | 2012-11-01 | — | — | US | claimed |
| WO-2012007019-A1 | PROCESS FOR THE PREPARATION OF CLOPIDOGREL AND SALTS THEREOF | PHARMATHEN S.A. (GR) | 2012-01-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120291663-A1 | PHASE CHANGE INK COMPONENTS AND METHODS OF MAKING THE SAME | ALK, TARDBP, MAPT | ALDH1A1 814/4885TDP1 38/4885MAPK1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.